Title: Research progress of chimeric antigen receptor T cell therapy for malignant hematologic diseases
Abstract: Chimeric antigen receptor (CAR) -T cell therapy is an emerging immunotherapy. Genes encoding fusion proteins of tumor cells antigen recognizing receptors and intracellular signaling domains of T cells recombined ex vivo, subsequently these plasmids were transfected into the T cells. Thus the T cells engineered to express a CAR could recognize special antigen on tumor cells and attack these cells. Currently CAR-T cell therapy showing striking effective in malignant tumor, especially in hematological malignancies, but the efficiency, safety, side effect, quality control of CAR-T cell therapy still need to be confirmed. In this review, we will introduce and discuss the CAR design, CAR-T cell manufacture, clinical trials and side effects in CAR-T cell therapy.
Key words:
Chimeric antigen receptor; T cell; Malignant hematologic diseases; Immunotherapy
Publication Year: 2016
Publication Date: 2016-11-20
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot